Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. They will advance a range of conjugates, unlimited by indication, using their own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Biotechnology

Tubulis

Dominik Schumacher

Katharina Heinzelmann

Dietmar König

Natascia Leonardi

Lisa Graßl

Eckart Frehe

Andreas Montag

Jan Felber

Judith Fuchsgruber

Izabela Kozlowska

Anil P. Jagtap

Annabel Kitowski

Julia Stiegeler

Elke Hammerbacher

Ralf Weidner

Ruzica Barisic

Ines Vasconcelos

Jonas Helma-Smets

Mary Ann Lumiqued

Günter Fingerle-Rowson

Armin Weidmann

Ingo Lehrke

Olivier Marcq

Research and Development Team

Advisory Team

Leadership Team

Operations

Research and Development

Quality Assurance Team

��

Teams at Tubulis

Research and Development Team

Advisory Team

Leadership Team

Operations

Research and Development

Quality Assurance Team

��������

Teams at Tubulis

Research and Development Team

Advisory Team

Leadership Team

Operations

Research and Development

Quality Assurance Team

��